Bank of America reissued an underperform rating for Amphastar Pharmaceuticals on June 29, 2026.
4 reports, 2 independent
Updated Jun 29
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bank of America reissued an underperform rating for Amphastar Pharmaceuticals on June 29, 2026.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Bank of America downgraded Amphastar Pharmaceuticals to Underperform.1 source
Amphastar's underperform rating was reaffirmed and price target lowered, alongside a buy rating from Berenberg Bank.1 source
Keep exploring
The entities involved
-
Amphastar Pharmaceuticals
publicly traded American pharmaceutical company
Nothing else this week.
-
Bank of America
American multinational banking and financial services corporation
Related events
- Bank of America, Benchmark, Benzinga, and MarketBeat provided various stock ratings and updates for Skyworks Solutions.
- Bank of America updated its price objective and rating, while Citigroup reissued a neutral rating on Biogen shares.
- Bank of America set a buy rating and price target for Penguin Solutions on October 23, 2026.